Simple Summary Ductal carcinoma in situ (DCIS) is a potential precursor to invasive breast
cancer (IBC). Although in many women DCIS will never become breast cancer, almost all …

Introduction: The ongoing development of genomic medicine and the use of molecular and
imaging markers in personalized medicine (PM) has arguably challenged the field of health …

Whether wide excision with margins≥ 1 cm is sufficient treatment for small low-or
intermediate-grade ductal carcinoma in situ (DCIS) is unclear. This is an updated analysis of …

Often considered an “indolent” disease for which a treatment de-escalation is advocated,
ductal carcinoma in situ (DCIS) of the breast has been recently shown to be associated with …

Purpose To compare ipsilateral breast event (IBE) risks in patients with ductal carcinoma in
situ of the breast (DCIS) post-lumpectomy, as estimated by breast radiation oncologists, the …

Background Guidelines recommend shared decision-making (SDM) around mammography
screening for women≥ 75 years old. Objective To use microsimulation modeling to estimate …

Background. Endocrine therapy initiation after ductal carcinoma in situ (DCIS) is highly
variable and largely unexplained. National guidelines recommend considering tamoxifen for …

Women diagnosed with DCIS face complex treatment decisions and often do so with
inaccurate and incomplete understanding of the risks and benefits involved. Our objective …

Objective Decision-making in ductal carcinoma in situ (DCIS) is complex due to the
heterogeneity of the disease. This study aimed to understand women's experience of …

PURPOSE Recent studies, including a meta-analysis of 88 trials, have shown higher than
expected rates of recurrence and death in hormone receptor–positive breast cancer. These …